source
- STAT+: Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricingThe pharma industry saw its reputation among patient groups inch up last year, a new survey finds, but concerns remain over access and pricing.STAT · 3mo ago↗ source
- STAT+: A new attack on AMA’s billing codesA key GOP lawmaker is broadening the party's efforts to combat health care fraud.STAT · 3mo ago↗ source
- Viridian data lift prospects for thyroid eye disease drugWhereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.BioPharma Dive · 3mo ago↗ source